Active, Not Recruiting
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed - CA209-8RX
Updated: 7 September, 2021 | ClinicalTrials.gov
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease. - Decision to treat with adjuvant nivolumab therapy has already been taken - At least 18 years of age at the time of treatment decision - Patients who provide written informed consent to participate in the study (for retrospectively enrolled patients who are deceased at time of study start, a consent waiver will be sought) Exclusion Criteria: - Any patient with a diagnosis of persisting advanced melanoma prior to first administration of nivolumab - Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for Overall Survival (OS)/ Relapse Free Survival (RFS) can be enrolled. In case of a blinded study, the treatment arm needs to be known). Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
